Clinical Trial Update: Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 [Phase 3]

View source ↗

Summary

Phase 3 trial update assessing long-term persistence and the effect of a booster dose of the IC51 Japanese encephalitis vaccine, sponsored by Valneva; results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• IC51 Japanese Encephalitis Vaccine (inactivated Japanese encephalitis vaccine IC51)

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Japanese Encephalitis | Phase 3 | Status: COMPLETED | Results posted: 2014-03-07